tiprankstipranks
Immunome, Inc. (IMNM)
NASDAQ:IMNM
US Market
IMNM
Immunome
RESEARCH TOOLSreports
Want to see IMNM full AI Analyst Report?

Immunome (IMNM) Stock Forecast & Price Target

463 Followers
See the Price Targets and Ratings of:

IMNM Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Immunome
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IMNM Stock 12 Month Forecast

Average Price Target

$36.00
▲(62.09% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Immunome in the last 3 months. The average price target is $36.00 with a high forecast of $40.00 and a low forecast of $30.00. The average price target represents a 62.09% change from the last price of $22.21.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","41":"$41","16.25":"$16.25","24.5":"$24.5","32.75":"$32.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,16.25,24.5,32.75,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.76,24.08615384615385,25.412307692307692,26.73846153846154,28.064615384615387,29.39076923076923,30.716923076923077,32.043076923076924,33.36923076923077,34.69538461538461,36.02153846153846,37.347692307692306,38.673846153846156,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.76,23.77846153846154,24.79692307692308,25.815384615384616,26.833846153846153,27.852307692307694,28.87076923076923,29.88923076923077,30.907692307692308,31.926153846153845,32.94461538461539,33.963076923076926,34.98153846153846,{"y":36,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.76,23.31692307692308,23.873846153846156,24.430769230769233,24.98769230769231,25.544615384615387,26.101538461538464,26.658461538461538,27.215384615384615,27.77230769230769,28.32923076923077,28.886153846153846,29.443076923076923,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.32,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.48,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.14,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.21,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.73,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.78,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.49,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.76,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$40.00Average Price Target$36.00Lowest Price Target$30.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on IMNM
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$31→$35
Buy
57.59%
Upside
Reiterated
08/12/26
Wedbush Sticks to Their Buy Rating for Immunome (IMNM)
Guggenheim Analyst forecast on IMNM
Michael Schmidt
Guggenheim
Guggenheim
$35
Buy
57.59%
Upside
Reiterated
08/12/26
Immunome (IMNM) Receives a Buy from Guggenheim
H.C. Wainwright Analyst forecast on IMNM
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$40
Buy
80.10%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Immunome (NASDAQ: IMNM) and Immunocore Holdings (NASDAQ: IMCR)
Evercore ISI Analyst forecast on IMNM
Cory Kasimov
Evercore ISI
Evercore ISI
$40
Buy
80.10%
Upside
Reiterated
08/12/26
Evercore ISI Remains a Buy on Immunome (IMNM)
LifeSci Capital Analyst forecast on IMNM
Charles Zhu
LifeSci Capital
LifeSci Capital
$40
Buy
80.10%
Upside
Reiterated
08/12/26
Immunome: Advancing Pipeline and Strong Cash Runway Underpin Reiterated Buy Rating and Unchanged $40 Price Target
Craig-Hallum Analyst forecast on IMNM
Adam Vogel
Craig-Hallum
Craig-Hallum
$36
Buy
62.09%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (NASDAQ: FENC) and Immunome (NASDAQ: IMNM)
Piper Sandler Analyst forecast on IMNM
Biren Amin
Piper Sandler
Piper Sandler
$33
Buy
48.58%
Upside
Reiterated
08/12/26
Piper Sandler Keeps Their Buy Rating on Immunome (IMNM)
Truist Financial Analyst forecast on IMNM
Supawat Thongthip
Truist Financial
Truist Financial
$37→$38
Buy
71.09%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Maze Therapeutics, Inc. (NASDAQ: MAZE) and Immunome (NASDAQ: IMNM)
TD Cowen Analyst forecast on IMNM
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Barclays Analyst forecast on IMNM
Lukas Shumway
Barclays
Barclays
$36
Buy
62.09%
Upside
Reiterated
08/11/26
Barclays Sticks to Its Buy Rating for Immunome (IMNM)
J.P. Morgan Analyst forecast on IMNM
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/29/26
Analyst Brian Cheng Initiates Buy on Immunome, Citing Differentiated Pipeline and Compelling Risk‑Reward Profile
Lake Street Analyst forecast on IMNM
Chad Messer
Lake Street
Lake Street
$30
Buy
35.07%
Upside
Reiterated
06/01/26
Lake Street Remains a Buy on Immunome (IMNM)
Leerink Partners Analyst forecast on IMNM
Andrew Berens
Leerink Partners
Leerink Partners
$37→$33
Buy
48.58%
Upside
Reiterated
05/15/26
Immunome price target lowered to $33 from $37 at LeerinkImmunome price target lowered to $33 from $37 at Leerink
Goldman Sachs Analyst forecast on IMNM
Salveen Richter
Goldman Sachs
Goldman Sachs
$35
Buy
57.59%
Upside
Reiterated
05/13/26
Immunome Price Target Maintained at $35 as Analyst Sees Best-in-Class Potential for Varegacestat in Desmoid Tumors
Stephens Analyst forecast on IMNM
Sudan Loganathan
Stephens
Stephens
$30
Buy
35.07%
Upside
Assigned
03/04/26
Immunome price target lowered to $30 from $33 at StephensImmunome price target lowered to $30 from $33 at Stephens
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on IMNM
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$31→$35
Buy
57.59%
Upside
Reiterated
08/12/26
Wedbush Sticks to Their Buy Rating for Immunome (IMNM)
Guggenheim Analyst forecast on IMNM
Michael Schmidt
Guggenheim
Guggenheim
$35
Buy
57.59%
Upside
Reiterated
08/12/26
Immunome (IMNM) Receives a Buy from Guggenheim
H.C. Wainwright Analyst forecast on IMNM
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$40
Buy
80.10%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Immunome (NASDAQ: IMNM) and Immunocore Holdings (NASDAQ: IMCR)
Evercore ISI Analyst forecast on IMNM
Cory Kasimov
Evercore ISI
Evercore ISI
$40
Buy
80.10%
Upside
Reiterated
08/12/26
Evercore ISI Remains a Buy on Immunome (IMNM)
LifeSci Capital Analyst forecast on IMNM
Charles Zhu
LifeSci Capital
LifeSci Capital
$40
Buy
80.10%
Upside
Reiterated
08/12/26
Immunome: Advancing Pipeline and Strong Cash Runway Underpin Reiterated Buy Rating and Unchanged $40 Price Target
Craig-Hallum Analyst forecast on IMNM
Adam Vogel
Craig-Hallum
Craig-Hallum
$36
Buy
62.09%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (NASDAQ: FENC) and Immunome (NASDAQ: IMNM)
Piper Sandler Analyst forecast on IMNM
Biren Amin
Piper Sandler
Piper Sandler
$33
Buy
48.58%
Upside
Reiterated
08/12/26
Piper Sandler Keeps Their Buy Rating on Immunome (IMNM)
Truist Financial Analyst forecast on IMNM
Supawat Thongthip
Truist Financial
Truist Financial
$37→$38
Buy
71.09%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Maze Therapeutics, Inc. (NASDAQ: MAZE) and Immunome (NASDAQ: IMNM)
TD Cowen Analyst forecast on IMNM
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Barclays Analyst forecast on IMNM
Lukas Shumway
Barclays
Barclays
$36
Buy
62.09%
Upside
Reiterated
08/11/26
Barclays Sticks to Its Buy Rating for Immunome (IMNM)
J.P. Morgan Analyst forecast on IMNM
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/29/26
Analyst Brian Cheng Initiates Buy on Immunome, Citing Differentiated Pipeline and Compelling Risk‑Reward Profile
Lake Street Analyst forecast on IMNM
Chad Messer
Lake Street
Lake Street
$30
Buy
35.07%
Upside
Reiterated
06/01/26
Lake Street Remains a Buy on Immunome (IMNM)
Leerink Partners Analyst forecast on IMNM
Andrew Berens
Leerink Partners
Leerink Partners
$37→$33
Buy
48.58%
Upside
Reiterated
05/15/26
Immunome price target lowered to $33 from $37 at LeerinkImmunome price target lowered to $33 from $37 at Leerink
Goldman Sachs Analyst forecast on IMNM
Salveen Richter
Goldman Sachs
Goldman Sachs
$35
Buy
57.59%
Upside
Reiterated
05/13/26
Immunome Price Target Maintained at $35 as Analyst Sees Best-in-Class Potential for Varegacestat in Desmoid Tumors
Stephens Analyst forecast on IMNM
Sudan Loganathan
Stephens
Stephens
$30
Buy
35.07%
Upside
Assigned
03/04/26
Immunome price target lowered to $30 from $33 at StephensImmunome price target lowered to $30 from $33 at Stephens
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunome

3 Months
Chad MesserLake Street
Success Rate
7/9 ratings generated profit
78%
Average Return
+18.93%
Copying Chad Messer's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +18.93% per trade.
1 Year
Chad MesserLake Street
Success Rate
9/9 ratings generated profit
100%
Average Return
+83.63%
Copying Chad Messer's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +83.63% per trade.
2 Years
Chad MesserLake Street
Success Rate
9/9 ratings generated profit
100%
Average Return
+105.29%
Copying Chad Messer's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +105.29% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMNM Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
12
20
20
21
11
Buy
9
12
10
11
17
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
32
30
32
28
In the current month, IMNM has received 28 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IMNM average Analyst price target in the past 3 months is 36.00.
Each month's total comprises the sum of three months' worth of ratings.

IMNM Financial Forecast

IMNM Earnings Forecast

Next quarter’s earnings estimate for IMNM is -$0.60 with a range of -$0.71 to -$0.41. The previous quarter’s EPS was -$0.65. IMNM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IMNM has Performed in-line its overall industry.
Next quarter’s earnings estimate for IMNM is -$0.60 with a range of -$0.71 to -$0.41. The previous quarter’s EPS was -$0.65. IMNM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IMNM has Performed in-line its overall industry.

IMNM Sales Forecast

Next quarter’s sales forecast for IMNM is $167.00K with a range of $0.00 to $2.00M. The previous quarter’s sales results were $0.00. IMNM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IMNM has Performed in-line its overall industry.
Next quarter’s sales forecast for IMNM is $167.00K with a range of $0.00 to $2.00M. The previous quarter’s sales results were $0.00. IMNM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IMNM has Performed in-line its overall industry.

IMNM Stock Forecast FAQ

What is IMNM’s average 12-month price target, according to analysts?
Based on analyst ratings, Immunome, Inc.’s 12-month average price target is 36.00.
    What is IMNM’s upside potential, based on the analysts’ average price target?
    Immunome, Inc. has 62.09% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IMNM a Buy, Sell or Hold?
          Immunome, Inc. has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Immunome, Inc.’s price target?
            The average price target for Immunome, Inc. is 36.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $40.00 ,the lowest forecast is $30.00. The average price target represents 62.09% Increase from the current price of $22.21.
              What do analysts say about Immunome, Inc.?
              Immunome, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of IMNM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.